AdAlta (ASX: 1AD), an Australian biotechnology company on its lead i-body therapeutic AD-214 for human clinical trials for Idiopathic Pulmonary Fibrosis, has appointed Dr Rosalind (Ros) Wilson to the role of non-executive director.
Dr Wilson has more than two decades of experience through a number of senior leadership and advisory roles with leading international pharmaceutical and smaller biotechnology companies.
Dr Wilson is clinically trained with experience in devising and implementing clinical research strategy, product life-cycle management and business development.
The company said this experience will be invaluable as it prepares for planned phase 1 clinical studies in early 2020.
Dr Wilson has held strategy and portfolio management roles at global pharmaceutical company F. Hoffmann - La Roche (Roche), including as global team leader for pertuzumab, a targeted monoclonal antibody developed for breast cancer, and the global team leader for a leading metabolic medicine.
Dr Wilson was most recently the CEO of ASX-listed Factor Therapeutics (ASX:FTT), a biomedical technology company developing therapeutics for advanced wound care.
“We are thrilled to have someone of Ros’ calibre join the AdAlta Board. Her expertise in clinical drug development and commercialisation, particularly in the global pharmaceutical space and her experience in lung disease garnered at Lung Foundation Australia will be of significant benefit as we progress development of our lead fibrosis candidate, AD-214,” said AdAlta chairman Paul McLeman.
Dr Wilson added, “I’m excited to be joining AdAlta at this crucial time. Not only are new therapies for IPF desperately needed, but the commercial landscape is extremely promising, with transactions occurring very early in the clinical development pathway. I look forward to contributing to the company's efforts as it nears the critical milestone of phase I human trials for AD-214, and assisting in bringing this drug and AdAlta’s other unique therapies to market.”